Patent foramen ovale and ventricular septal defect closure

Heart

Volumn 95, Issue 1, 2009, Pages 70-82

  Wahl, A ^a   Meier, B ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL;

ADULT; ATRIOVENTRICULAR CONDUCTION; BACTERIAL ENDOCARDITIS; DEVICE; EMBOLISM; FEMALE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INVASIVE PROCEDURE; MORBIDITY; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BALLOON OCCLUSION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; EMBOLISM; EQUIPMENT DESIGN; FEMALE; FORAMEN OVALE, PATENT; FORECASTING; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 58349084651     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2007.121038     Document Type: Review

References (101)

1. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59:17-20.
2. Wilmshurst PT, Pearson MJ, Nightingale S, et al. Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura. Heart 2004; 90:1315-20.
3. Silver MD, Dorsey JS. Aneurysms of the septum primum in adults. Arch Pathol Lab Med 1978; 102:62-5.
4. Hanley PC, Tajik AJ, Hynes JK, et al. Diagnosis and classification of atrial septal aneurysm by two-dimensional echocardiography: report of 80 consecutive cases. J Am Coll Cardiol 1985; 6:1370-82.
5. Pearson AC, Nagelhout D. Castello R, et al. Atrial septal aneurysm and stroke: a transesophageal echocardiographic study. J Am Coll Cardiol 1991; 18:1223-9.
6. Agmon Y, Khandheira BK, Meissner I, et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation 1999; 99:1942-4.
7. Minette MS, Sahn DJ. Ventricular septal defects. Circulation 2006; 114:2190-7.
8. Moller JH, Patton C, Varco RL, et al. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol 1991; 68:1491-7.
9. Nygren A, Sunnegardh J, Berggren H. Preoperative evaluation and surgery in isolated ventricular septal defects: a 21 year perspective. Heart 2000; 83:198-204.
10. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993; 87:138-51.
11. King TD, Thompson SL, Steiner C, et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA 1976; 235:2506-9.
12. Rashkind WJ. Transcatheter treatment of congenital heart disease. Circulation 1983; 67:711-6.
13. Sideris EB, Sideris SE, Fowlkes JP, et al. Transvenous atrial septal defect occlusion in piglets with a "buttoned" double-disk device. Circulation 1990; 81:312-8.
14. Windecker S, Wahl A, Chatterjee T, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000; 101:893-8.
15. Hung J, Landzberg MJ, Jenkins KJ, et al. Closure of patent foramen ovale for paradoxical emboli: intermediate-term. J Am Coll Cardiol 2000; 35:1311-6.
16. Wahl A, Meier B, Haxel B, et al. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology 2001; 57:1330-2.
17. Martin F, Sanchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002; 106:1121-6.
18. Braun MU, Fassbender D, Schoen SP, et al. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 2002; 39:2019-25.
19. Braun M, Gliech V, Boscheri A. et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J 2004; 25:424-30.
20. Wahl A, Krumsdorf U, Meier B, et al. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recunent paradoxical embolism in high-risk patients. J Am Coll Cardiol 2005; 45:377-80.
21. Lock JE, Block PC, McKay RG, et al. Transcatheter closure of ventricular septal defects. Circulation 1988; 78:361-8.
22. Thanopoulos BD, Tsaousis GS, Konstadopoulou GN, et al. Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: initial clinical applications in children. J Am Coll Cardiol 1999; 33:1395-9.
23. Hijazi ZM, Hakim F, Al-Fadley F, et al. Transcatheter closure of single muscular ventricular septal defects using the amplatzer muscular VSD occluder: initial results and technical considerations. Catheter Cardiovasc Interv 2000; 49:167-72.
24. Arora R, Trehan V, Thakur AK, et al. Transcatheter closure of congenital muscular ventricular septal defect. J Interv Cardiol 2004; 17:109-15.
25. Fu YC, Bass J, Amin Z, et al. Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: results of the U.S. phase I trial. J Am Coll Cardiol 2006; 47:319-25.
26. Thanopoulos BV, Rigby ML, Karanasios E, et al. Transcatheter closure of perimembranous ventricular septal defects in infants and children using the Amplatzer perimembranous ventricular septal defect occluder. Am J Cardiol 2007; 99:984-9.
27. Holzer R, de Giovanni J, Walsh KP, et al. Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: immediate and midterm results of an international registry. Catheter Cardiovasc Interv 2006; 68:620-8.
28. Homma S, Di Tullio MR, Sacco RL, et al. Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke 1994; 25:582-6.
29. Steiner MM, Di Tullio MR, Rundek T, et al. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 1998; 29:944-8.
30. Hausmann D, Mugge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol 1995; 26:1030-8.
31. Schuchlenz HW, Weihs W, Homer S, et al. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med 2000; 109:456-62.
32. Stone DA, Godard J, Corretti MC, et al. Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J 1996; 131:158-61.
33. De Castro S, Cartoni D, Fiorelli M, et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke 2000; 31:2407-13.
34. Overall JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a metaanalysis of case-control studies. Neurology 2000; 55:1172-9.
35. Onorato E, Melzi G, Casilli F, et al. Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients. J Interv Cardiol 2003; 16:43-50.
36. Meier B. Pacman sign during device closure of the patent foramen ovale. Catheter Cardiovasc Interv 2003; 60:221-3.
37. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43:302-9.
38. Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25:382-90.
39. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318:1148-52.
40. Webster MW, Chancellor AM, Smith HJ, et al. Patent foramen ovale in young stroke patients. Lancet 1988; 2:11-2.
41. de Bolder MA, Tourikis L, Leech G, et al. Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol 1992; 69:1316-20.
42. Di Tullio M, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992; 117:461-5.
43. Hausmann D, Mugge A, Becht I, et al. Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. Am J Cardiol 1992; 70:668-72.
44. Cabanes L, Mas JL, Cohen A, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993; 24:1865-73.
45. Jones EF, Calafiore P, Donnan GA, et al. Evidence that patent foramen ovale is not a risk factor for cerebral ischemia in the elderly. Am J Cardiol 1994; 74:596-9.
46. Bogousslavsky J, Garazi S, Jeanrenaud X, et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 1996; 46:1301-5.
47. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 1995; 130:1083-8.
48. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345:1740-6.
49. Nedeltchev K, Arnold M, Wahl A, et al. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry 2002; 72:347-50.
50. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105:2625-31.
51. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003; 139:753-60.
52. Windecker S, Wahl A, Nedeltchev K, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 2004; 44:750-8.
53. Mugge A, Daniel WG, Angermann C, et al. Atrial septal aneurysm in adult patients. A multicenter study using transthoracic and transesophageal echocardiography. Circulation 1995; 91:2785-92.
54. Mattioli AV, Aquilina M, Oldani A, et al. Atrial septal aneurysm as a cardioembolic source in adult patients with stroke and normal carotid arteries. A multicentre study. Eur Heart J 2001; 22:261-8.
55. Schneider B, Hanrath P, Vogel P, et al. Improved morphologic characterization of atrial septal aneurysm by transesophageal echocardiography: relation to cerebrovascular events. J Am Coll Cardiol 1990; 16:1000-9.
56. Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003; 107:5-9.
57. Meier B. Patent foramen ovale, guilty but only as a gang member and for a lesser crime. J Am Coll Cardiol 2006; 47:446-8.
58. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933-8.
59. Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv 2006; 68:136-42.
60. Sukernik MR, Mets B, Bennett-Guerrero E. Patent foramen ovale and its significance in the perioperative period. Anesth Analg 2001; 93:1137-46.
61. Seward JB, Hayes DL, Smith HC, et al. Platypnea- orthodeoxia: clinical profile, diagnostic workup, management, and report of seven cases. Mayo Clin Proc 1984; 59:221-31.
62. Silver MT, Lieberman EH, Thibault GE. Refractory hypoxemia in inferior myocardial infarction from right-to-left shunting through a patent foramen ovale: a case report and review of the literature. Clin Cardiol 1994; 17:627-30.
63. Konstantinides S, Geibel A, Kasper W, et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 1998; 97:1946-51.
64. Shanoudy H, Soliman A, Raggi P, et al. Prevalence of patent foramen ovale and its contribution to hypoxemia in patients with obstructive sleep apnea. Chest 1998; 113:91-6.
65. Agnoletti G, Iserin L, Lafont A, et al. Obstructive sleep apnoea and patent foramen ovale: successful treatment of symptoms by percutaneous foramen ovale closure. J Interv Cardiol 2005; 18:393-5.
66. Germonpre P, Dendale P, Unger P, et al. Patent foramen ovale and decompression sickness in sports divers. J Appl Physiol 1998; 84:1622-6.
67. Schwerzmann M, Seiler C, Lipp E, et al. Relation between directly detected patent foramen ovale and ischemic brain lesions in sport divers. Ann Intern Med 2001; 134:21-4.
68. Post MC, Luermans JG, Plokker HW, et al. Patent foramen ovale and migraine. Catheter Cardiovasc Interv 2007; 69:9-14.
69. Del Sette M, Angeli S, Leandri M, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis 1998; 8:327-30.
70. Anzola GP, Magoni M, Guindani M, et al. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999; 52:1622-5.
71. Schwerzmann M, Nedeltchev K, Lagger F, et al. Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology 2005; 65:1415-8.
72. Sztajzel R, Genoud D, Roth S, et al. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc Dis 2002; 13:102-6.
73. Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci (Lond) 2001; 100:215-20.
74. Anzola GP, Frisoni GB, Morandi E, et al. Shunt-associated migraine responds favorably to atrial septal repair: a case-control study. Stroke 2006; 37:430-4.
75. Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008; 117:1397-404
76. Post MC, Thijs V, Schonewille WJ, et al. Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine. Neurology 2006; 66:202-5.
77. Schwerzmann M, Windecker S, Wahl A, et al. Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy. Heart 2004; 90:186-90.
78. Schoen SP, Boscheri A, Lange SA, et al. Incidence of aortic valve regurgitation and outcome after percutaneous closure of atrial septal defects and patent foramen ovale. Heart 2008; 94:844-7.
79. Andersen HO, de Leval MR, Tsang VT, et al. Is complete heart block after surgical closure of ventricular septum defects still an issue? Ann Thorac Surg 2006; 82:948-56.
80. Mullen MJ, Hildick-Smith D, De Giovanni JV, et al. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation 2006; 114:1962-7.
81. Dearani JA, Ugurlu BS, Danielson GK, et al. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation 1999; 100:∥171-5.
82. Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation 1992; 86:1902-8.
83. Ende DJ, Chopra PS, Rao PS. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of recurrence of paradoxic embolism. Am J Cardiol 1996; 78:233-6.
84. Wahl A, Kunz M, Moschovitis A, et al. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart 2008; 94:336-41.
85. Bijl JM, Ruygrok PN, Hornung TS, et al. Percutaneous closure of patent foramen ovale. Intern Med J 2005; 35:706-10.
86. Bruch L, Parsi A, Grad MO, et al. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: single-center experience. Circulation 2002; 105:2845-8.
87. Spies C, Strasheim R, Timmermanns I, et al. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder. Eur Heart J 2006; 27:365-71.
88. Khositseth A, Cabalka AK, Sweeney JP, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc 2004; 79:35-41.
89. Alameddine F, Block PC. Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: acute results from the FORECAST registry. Catheter Cardiovasc Interv 2004; 62:512-6.
90. Chatterjee T, Petzsch M, Ince H, et al. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol 2005; 18:173-9.
91. Buschack F, Sievert H, Kleber F, et al. Patent foramen ovale using the Premere device: the results of the CLOSEUP trial. J Interv Cardiol 2006; 19:328-33.
92. Slavin L, Tobis JM, Rangarajan K, et al. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol 2007; 99:1316-20.
93. Harms V, Reisman M, Fuller CJ, et al. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Am J Cardiol 2007; 99:1312-5.
94. Wilmshurst PT, Nightingale S, Walsh KP, et al. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000; 356:1648-51.
95. Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004; 62:1399-401.
96. Post MC, Thijs V, Herroelen L, et al. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004; 62:1439-40.
97. Azarbal B, Tobis J, Suh W, et al. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 2005; 45:489-92.
98. Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005; 45:493-5.
99. Giardini A, Donti A, Formigari R, et al. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. Am Heart J 2006; 151:922 e1-5.
100. Slavin L, Tobis JM, Rangarajan K, et al. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol 2007; 99:1316-20.
101. Morandi E, Anzola GP, Angeli S, et al. Transcatheter closure of patent foramen ovale: a new migraine treatment? J Interv Cardiol 2003; 16:39-42